Literature DB >> 12217604

Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD).

Samuel S Lee1, E Jenny Heathcote, K Rajender Reddy, Stefan Zeuzem, Michael W Fried, Teresa L Wright, Paul J Pockros, Dieter Häussinger, Coleman I Smith, Amy Lin, Stephen C Pappas.   

Abstract

BACKGROUND/AIMS: Baseline factors and early decline in serum hepatitis C virus RNA are predictive of sustained virological response to interferon therapy in patients with chronic hepatitis C. We evaluated the prognostic value of baseline factors and early viral RNA among patients treated with peginterferon alfa-2a (40KD).
METHODS: Data were pooled from three randomized trials involving 814 patients treated with peginterferon alfa-2a (40KD) (90, 135, or 180 mirog). Stepwise and multiple logistic regression identified independent baseline factors associated with response. Receiver operating characteristic curves for both absolute values and log(10) decline in viral RNA at 4, 8, 12 and 24 weeks of therapy were created.
RESULTS: Independent prognostic factors for sustained virological response included viral genotype non-1, low pretreatment viral load, age (<40 years), no cirrhosis and body weight (<85 kg). In addition, alanine aminotransferase quotient (>3) and histological activity index score (>10) were also independently prognostic. Receiver operating characteristic curves showed that detectable or less than 2-log(10) decline in viral RNA at week 12 predicted sustained virological non-response (negative predictive value is 98%) .
CONCLUSIONS: In patients with chronic hepatitis C treated with peginterferon alfa-2a (40KD), the decision to continue or stop treatment can be made as early as week 12.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12217604     DOI: 10.1016/s0168-8278(02)00211-8

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  25 in total

Review 1.  Laboratory assays for diagnosis and management of hepatitis C virus infection.

Authors:  Sandra S Richter
Journal:  J Clin Microbiol       Date:  2002-12       Impact factor: 5.948

2.  Rapid virological response to peginterferon alfa and ribavirin treatment of chronic hepatitis C predicts sustained virological response and relapse in genotype 1 patients.

Authors:  Fred Poordad; Carmen Landaverde
Journal:  Therap Adv Gastroenterol       Date:  2009-03       Impact factor: 4.409

3.  Excellent superiority and specificity of COBAS TaqMan HCV assay in an early viral kinetic change during pegylated interferon alpha-2b plus ribavirin treatment.

Authors:  Eiichi Ogawa; Norihiro Furusyo; Kazuhiro Toyoda; Hiroaki Taniai; Shigeru Otaguro; Mosaburo Kainuma; Masayuki Murata; Yasunori Sawayama; Jun Hayashi
Journal:  BMC Gastroenterol       Date:  2010-04-16       Impact factor: 3.067

4.  Cutaneous Sarcoidosis: An Uncommon Side Effect of Pegylated Interferon and Ribavirin Use for Chronic Hepatitis C.

Authors:  Elson Vidal Martins; Ana Karla Gaburri; Debora Gaburri; Angelo Sementilli
Journal:  Case Rep Gastroenterol       Date:  2009-11-21

5.  Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C.

Authors:  Hatsue Fujino; Michio Imamura; Yuko Nagaoki; Yoshiiku Kawakami; Hiromi Abe; C Nelson Hayes; Hiromi Kan; Takayuki Fukuhara; Tomoki Kobayashi; Keiichi Masaki; Atsushi Ono; Takashi Nakahara; Youji Honda; Noriaki Naeshiro; Ayako Urabe; Satoe Yokoyama; Daisuke Miyaki; Eisuke Murakami; Tomokazu Kawaoka; Nobuhiko Hiraga; Masataka Tsuge; Akira Hiramatsu; Hideyuki Hyogo; Hiroshi Aikata; Shoichi Takahashi; Daiki Miki; Hidenori Ochi; Waka Ohishi; Kazuaki Chayama
Journal:  J Gastroenterol       Date:  2013-12-21       Impact factor: 7.527

6.  Improved COBAS TaqMan hepatitis C virus test (Version 2.0) for use with the High Pure system: enhanced genotype inclusivity and performance characteristics in a multisite study.

Authors:  G Colucci; J Ferguson; C Harkleroad; S Lee; D Romo; S Soviero; J Thompson; M Velez; A Wang; Y Miyahara; S Young; C Sarrazin
Journal:  J Clin Microbiol       Date:  2007-09-26       Impact factor: 5.948

7.  Multicenter evaluation of the performance characteristics of the bayer VERSANT HCV RNA 3.0 assay (bDNA).

Authors:  Tarek Elbeik; Johan Surtihadi; Mark Destree; Jed Gorlin; Mark Holodniy; Saeed A Jortani; Ken Kuramoto; Valerie Ng; Roland Valdes; Alexandra Valsamakis; Norah A Terrault
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

Review 8.  Peginterferon-alpha-2a (40 kD) plus ribavirin: a review of its use in the management of chronic hepatitis C mono-infection.

Authors:  Susan J Keam; Risto S Cvetković
Journal:  Drugs       Date:  2008       Impact factor: 9.546

9.  Evaluation of an automated nucleic acid extractor for hepatitis C virus load quantification.

Authors:  Elisa Martró; Nerea García-Sierra; Victoria González; Verónica Saludes; Lurdes Matas; Vicenç Ausina
Journal:  J Clin Microbiol       Date:  2009-01-07       Impact factor: 5.948

10.  Factors associated with rapid and early virologic response to peginterferon alfa-2a/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population.

Authors:  M Rodriguez-Torres; M S Sulkowski; R T Chung; F M Hamzeh; D M Jensen
Journal:  J Viral Hepat       Date:  2009-08-05       Impact factor: 3.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.